Advaxis, a biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases, announced the appointment of Daniel J. O'Connor to the position of Senior Vice President, Chief Legal and Business Development Officer. Mr. O'Connor joins the management team with fifteen years of executive, legal, and regulatory experience in the biopharmaceutical industry.
"We are delighted to welcome Dan O'Connor to Advaxis," stated Thomas Moore, Advaxis' Chairman and Chief Executive Officer. "Now that our clinical development has reached an advanced stage, his success as a general counsel and in leading business development and licensing negotiations is a timely addition to our management team. We are very fortunate to attract a highly experienced professional of this caliber. It is a significant endorsement of Advaxis' immunotherapy technology and our potential to unlock unrealized enterprise value."
"I believe that Advaxis' future holds tremendous potential," commented Mr. O'Connor. "I look forward to continuing the company's culture of decisiveness and efficient execution. We will aggressively advance ADXS-HPV and our other pipeline product candidates, while building commercial alliances to both accelerate product development and generate shareholder value."
Joining ImClone in 2003, Mr. O'Connor supported the clinical development, launch, and commercialization of ERBITUX(NYSE:R). As ImClone's senior vice president, general counsel, and secretary, he played a key role in resolving numerous issues facing ImClone, including extensive licensing negotiations, in advance of the company being sold to Eli Lilly (NYSE: LLY) in 2008.
Prior to ImClone, Mr. O'Connor was PharmaNet's general counsel and instrumental in building the company from a start-up contract research organization to an established world leader in clinical research. Mr. O'Connor was also a criminal prosecutor in New Jersey and gained leadership experience as a Captain in the U.S. Marines, serving in the Persian Gulf in 1990. Most recently, while at Bracco Diagnostics, Mr. O'Connor was the company's vice president and general counsel.
For more information on Advaxis and its fifteen distinct constructs, all of which are involved in strategic collaborations with recognized centers of excellence, visit Advaxis.com
Let us hear your thoughts: Advaxis, Inc.. Message Board
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net